CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial
Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Bruno François(Inserm), Thierry Dugernier(Clinique Saint Pierre), Samareh Azeredo da Silveira, Gwenhaël Colin(Assistance Publique – Hôpitaux de Paris), Pierre‐François Dequin(Université de Tours), Thierry Boulain(Centre hospitalier universitaire d'Orléans), Antonio Perez(Biognosys (Switzerland)), Frédéric Lajaunias
Cited by 59
Related Papers
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure
|New England Journal of Medicine|2015|2.4k
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
|JAMA|2020|2.4k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
|Clinical Infectious Diseases|2014|1.1k